Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL - PubMed
6 hours ago
- #BTK Inhibitors
- #Chronic Lymphocytic Leukemia
- #Venetoclax
- The article discusses the shift toward patient-centered decision-making in fixed-duration therapy combining BTK inhibitors (BTKi) and venetoclax for chronic lymphocytic leukemia (CLL).
- It references key clinical trials, such as GLOW and CAPTIVATE, which show long-term efficacy and safety data for ibrutinib–venetoclax regimens compared to traditional treatments.
- The authors highlight the importance of considering patient preferences, comorbidities, and quality of life beyond just mechanistic drug efficacy when selecting treatment options.
- Competing interests include consultancy and research support from pharmaceutical companies like AbbVie, Johnson & Johnson, AstraZeneca, and Roche, indicating industry ties.
- Comparative analyses, such as between ibrutinib and acalabrutinib, are noted to inform efficacy evaluations in fixed-duration CLL therapy strategies.